Experts have recommended a temporary delay in second doses for people other than those with immune disorders while further information is sought, (file image) Photo: Aline Morcillo / Hans Lucas via AFP
There have been two reports of a possible link to pericarditis from the mpox vaccine.
Medsafe group manager Chris James said they were investigating but needed more information and encouraged people to report any suspected adverse reactions to the mpox vaccine.
Public Health director Dr Nick Jones said experts met on Thursday and agreed vaccination should continue to be made available to groups most at risk of mpox.
But they recommended a temporary delay in second doses for people other than those with immune disorders while further information was sought, Jones said.
Experts noted while two doses were recommended, good levels of protection were provided by a single dose in the medium term and advised a delay in the second dose might also improve long-term protection.
The technical advisory group also recommended a slight change in the way the vaccine was delivered, Jones said.
Vaccination will continue to be available only after a consultation with a prescribing doctor and prescribers are being provided with updated information about possible risks to inform those seeking vaccination.
The medical regulatory body will be reviewing information from overseas as part of their investigations into the reports.
Vaccine providers had been given information on the safety alert, Medsafe said.
Pericarditis is treatable, particularly with early detection and diagnosis.
Anyone receiving the vaccine is already alerted to the possible risk of pericarditis as a rare potential side effect of the mpox vaccine.
Medsafe is reminding vaccinated people to seek urgent medical attention if they experience symptoms following vaccination.
Anyone concerned or wanting more information should contact Healthline on 0800 611 116.
